Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orion Corporation
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.
With Nubeqa establishing itself as a strong option for prostate cancer, Bayer is shifting its short-term focus from oncology onto cardiovascular and plotting a late-stage plan for asundexian, its follow-up to Xarelto.
Four Chinese biotech companies reach in- and out-licensing deals covering antibody drug conjugates, small molecules and vaccines as they continue to pursue and develop innovation.
- Medical Devices
- Generic Drugs
- Other Names / Subsidiaries
- Orion Corporation
- Orion Diagnostica Oy
- Orion Pharma
- Orion Oyj